

## Product datasheet for **TL303641**

### Kallikrein 13 (KLK13) Human shRNA Plasmid Kit (Locus ID 26085)

#### Product data:

Product Type:	shRNA Plasmids
Product Name:	Kallikrein 13 (KLK13) Human shRNA Plasmid Kit (Locus ID 26085)
Locus ID:	26085
Synonyms:	KLK-L4; KLKL4
Vector:	pGFP-C-shLenti (TR30023)
E. coli Selection:	Chloramphenicol (34 ug/ml)
Mammalian Cell Selection:	Puromycin
Format:	Lentiviral plasmids
Components:	KLK13 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 26085). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
RefSeq:	<a href="#">NM_015596</a> , <a href="#">NM_001348177</a> , <a href="#">NM_001348178</a> , <a href="#">NR_145463</a> , <a href="#">NR_145464</a> , <a href="#">NR_145465</a> , <a href="#">NR_145466</a> , <a href="#">NR_145467</a> , <a href="#">NM_015596.1</a> , <a href="#">NM_015596.2</a> , <a href="#">BC069543</a> , <a href="#">BC069543.1</a> , <a href="#">BC069334</a> , <a href="#">NM_015596.3</a>
UniProt ID:	<a href="#">Q9UKR3</a>
Summary:	Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Expression of this gene is regulated by steroid hormones and may be useful as a marker for breast cancer. [provided by RefSeq, Jan 2017]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).